Trial Profile
Comparison of the Medication Adherence of Patients Treated With Telmisartan/Hydrochlorothiazide or Telmisartan/Amlodipine Fixed Dose Combination (FDC) Versus Double-pill Combination Therapy Based on Database Data in Real-world Japanese Therapeutic Practice
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase IV
Latest Information Update: 01 Jul 2022
Price :
$35
*
At a glance
- Drugs Amlodipine/telmisartan (Primary) ; Telmisartan/hydrochlorothiazide (Primary) ; Amlodipine; Telmisartan
- Indications Hypertension
- Focus Therapeutic Use
- Sponsors Boehringer Ingelheim
- 23 Jun 2022 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 16 Dec 2021 Planned End Date changed from 11 Jan 2022 to 11 Jul 2022.
- 16 Dec 2021 Planned primary completion date changed from 11 Jan 2022 to 11 Jul 2022.